Form 4: Stoke Therapeutics Director Ian F. Smith Acquires Stock Options

Director Ian F. Smith acquired stock options in Stoke Therapeutics, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Ian F. Smith, a director of Stoke Therapeutics, Inc., was granted stock options to purchase 7,639 shares of common stock.
• The exercise price of these options is $16.41 per share.
• The options vest on the earlier of June 5, 2025, or the date of the company's next annual meeting, contingent upon continued service to the issuer.
• The options expire on June 4, 2034.
• A Limited Power of Attorney was executed, appointing Edward M. Kaye, Jonathan Allan, and Thomas Leggett as attorneys-in-fact to handle SEC filings on behalf of Ian F. Smith.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction (stock option grant) and suggests confidence from the director in the company's future. It's a neutral-to-positive indicator.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is tied to continued service, suggesting an expectation of ongoing involvement.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotechnology companies.
• The vesting schedule of one year is fairly standard.
• Comparable companies such as Biogen, Vertex Pharmaceuticals, and Ionis Pharmaceuticals also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates